TY - JOUR
T1 - In vitro cytotoxicity of trastuzumab (Tz) and se-trastuzumab (se-tz) against the her/2 breast cancer cell lines jimt-1 and bt-474
AU - Bapat, Priyanka
AU - Sewell, Debalina Goswami
AU - Boylan, Mallory
AU - Sharma, Arun K.
AU - Spallholz, Julian E.
N1 - Funding Information:
Acknowledgments: This work was supported in part by The Department of Nutritional Sciences and the College of Human Sciences, Texas Tech University, Lubbock, TX, USA. Trastuzumab was kindly provided by Everardo Cobos of the TTUHSC Oncology Clinic. AKS thanks the Department of Pharmacology, Penn State College of Medicine, and Penn State Cancer Institute (PSCI) for financial support. The authors thank Organic Synthesis Shared Resource and Center for NMR Research Facilities of the Penn State College of Medicine.
Funding Information:
This work was supported in part by The Department of Nutritional Sciences and the College of Human Sciences, Texas Tech University, Lubbock, TX, USA. Trastuzumab was kindly provided by Everardo Cobos of the TTUHSC Oncology Clinic. AKS thanks the Department of Pharmacology, Penn State College of Medicine, and Penn State Cancer Institute (PSCI) for financial support. The authors thank Organic Synthesis Shared Resource and Center for NMR Research Facilities of the Penn State College of Medicine.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021
Y1 - 2021
N2 - Her/2+ breast cancer accounts for ~25% mortality in women and overexpression of Her/2 leads to cell growth and tumor progression. Trastuzumab (Tz) with Taxane is the preferred treatment for Her/2+ patients. However, Tz responsive patients often develop resistance to Tz treatment. Herein, redox selenides (RSe-) were covalently linked to Tz using a selenium (Se)-modified Bolton– Hunter Reagent forming Seleno-Trastuzumab (Se-Tz; ~25 µgSe/mg). Se-Tz was compared to Tz and sodium selenite to assess the viability of JIMT-1 and BT-474 cells. Comparative cell viability was examined by microscopy and assessed by fluorometric/enzymatic assays. Se-Tz and selenite redox cycle producing superoxide (O2•−) are more cytotoxic to Tz resistant JIMT-1 and Tz sensitive BT-474 cells than Tz. The results of conjugating redox selenides to Tz suggest a wider application of this technology to other antibodies and targeting molecules.
AB - Her/2+ breast cancer accounts for ~25% mortality in women and overexpression of Her/2 leads to cell growth and tumor progression. Trastuzumab (Tz) with Taxane is the preferred treatment for Her/2+ patients. However, Tz responsive patients often develop resistance to Tz treatment. Herein, redox selenides (RSe-) were covalently linked to Tz using a selenium (Se)-modified Bolton– Hunter Reagent forming Seleno-Trastuzumab (Se-Tz; ~25 µgSe/mg). Se-Tz was compared to Tz and sodium selenite to assess the viability of JIMT-1 and BT-474 cells. Comparative cell viability was examined by microscopy and assessed by fluorometric/enzymatic assays. Se-Tz and selenite redox cycle producing superoxide (O2•−) are more cytotoxic to Tz resistant JIMT-1 and Tz sensitive BT-474 cells than Tz. The results of conjugating redox selenides to Tz suggest a wider application of this technology to other antibodies and targeting molecules.
UR - http://www.scopus.com/inward/record.url?scp=85104887866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104887866&partnerID=8YFLogxK
U2 - 10.3390/ijms22094655
DO - 10.3390/ijms22094655
M3 - Article
C2 - 33925081
AN - SCOPUS:85104887866
SN - 1661-6596
VL - 22
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 9
M1 - 4655
ER -